1Sohal DP,Sun W. What is the reference cytotoxic regimenfor advanced gastric cancer : standard versus optimaltherapy[ J] . Expert Rev Anticancer Ther,2011,11( 12):1843 - 1850.
2Shah MA. Update on metastatic gastric and esophagealcancers[J]. J Clin Oncol,2015 ,33( 16) : 1760-1769.
3Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. PhaseIH study of docetaxel and cisplatin plus fluorouracilcompared with cisplatin and fluorouracil as flrstlinetherapy for advanced gastric cancer: a report of the V325Study Group [J]. J Clin Oncol,2006,24 ( 31 ) : 4991 -4997.
4Cunningham D,Starling N,Rao S,et al. Capecitabine andoxaliplatin for advanced esophagogastric cancer [ J ]. NEngl J Med ,2008,358(1) :36 -46.
5Al-Batran SE,Hartmann JT,Probst S,et aL Phase IH trialin metastatic chemotherapy for advanced gastric cancergastroesophageal adenocarcinoma with fluorouracil,leucovorin plus either oxaliplatin or cisplatin : a study ofthe Arbeitsgemeinschaft Intemistische Onkologie [ J ]. JClin Oncol,2008,26(9) : 1435 -1442.
6Dank M,Zaluski J,Barone C,et al. Randomized phase HIstudy comparing irinotecan combined with 5-fluorouraciland folinic acid to cisplatin combined with 5-fluorouracilin chemotherapy naive patients with advancedadenocarcinoma of the stomach or esophagogastricjunction[ J]. Ann Oncol,2008,19(8) : 1450 - 1457.
7Boku N,Yamamoto S, Fukuda H, et al. Fluorouracilversus combination of irinotecan plus cisplatin versus S-lin metastatic gastric cancer : a randomised phase 3 study[J]. Lancet Oncol,2009,10( 11) :1063 - 1069.
8Koizumi W,Narahara H,Hara T,et al. S-l plus cisplatinversus S-l alone for first-line treatment of advancedgastric cancer ( SPIRITS trial) : a phase IH trial [ J ] .Lancet Oncol,2008,9(3) :215 -221.
9Bang YJ, Van Cutsem E, Feyereislova A,et al.Trastuzumab in combination with chemotherapy versuschemotherapy alone for treatment of HER2-positiveadvanced gastric or gastro-oesophageal junction cancer(ToGA ) : a phase 3,open-label, randomised controlledtrial [ J ]. Lancet, 2010,376 (9742) : 687 -697.
10Bittoni A, Scartozzi M, Giampieri R, et al. Clinicalevidence for three distinct gastric cancer subtypes : Timefor a new approach [ J ]. PLoS One, 2013,8 ( 11 ):e78544.
